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UNIT 2.4A Base-Labile Protecting Group
(Fluorenylmethoxycarbonyl) for the
5′-Hydroxy Function of Nucleosides
Once the exocyclic amino functions of a nucleoside have been protected (UNIT 2.1), further
functionalization aimed towards assembly into oligonucleotides requires consideration
of the specific regioselective protection of the hydroxy groups present in the monomeric
building block. Some years ago it was found that, in the case of 2′-deoxynucleosides, the
two hydroxy groups (3′- and 5′-) could be satisfactorily differentiated by the application
of the triarylmethyl (trityl) family of acid-labile protecting groups for temporary protec-
tion of the primary 5′-hydroxy function (UNIT 2.3). In the case of the ribonucleoside series,
however, the differentiation of the three hydroxy groups (2′-, 3′-, and 5′-) has to be
achieved at the extremely high level of efficiency required for the iterative steps involved in
oligonucleotide assemblies carried out on synthesizer machines. This increased complexity
has led to a number of alternative synthetic pathways to oligoribonucleotides, some of which
are now commercialized; other pathways remain to be explored more profoundly.
Most of the present oligoribonucleotide synthesis strategies adhere to the popular 5′-O-
trityl chemistry and aim at finding solutions for 2′-O-protection (UNIT 2.2), such as the
t-butyldimethylsilyl (TBDMS) group, which can be removed by treatment with fluoride
ion. In contrast, the authors chose to take advantage of the well-established ketal-type
group for 2′-O-protection, which allows final deprotection under particularly mild and
isomerization-free acidolytic aqueous conditions at the end of the synthesis (UNIT 2.2), and
investigated for 5′-protection the base-labile 9-fluorenylmethoxycarbonyl (FMOC) group
as a valuable orthogonal complement. The following Basic Protocol presents a reliable
procedure for the regioselective introduction of the FMOC group at the 5′-hydroxy
position of nucleosides, starting with deoxythymidine or with 4-methoxytetrahy-
dropyran-4-yl (MTHP)–protected ribonucleosides. The Basic Protocol includes steps for
the isolation and characterization of all four 5′-O-FMOC-2′-O-MTHP-protected ribonu-
cleosides and of 5′-O-FMOC-2′-deoxythymidine, which serves as a reference for the
deoxyribonucleoside series. No modification is required for 5′-O-FMOC-2′-dABz, -dCBz,
or -dGi-Bu (yields are ~65% for dGi-Bu and 70% to 80% for dABz and dCBz; Balgobin and
Chattopadhyaya, 1987; Ma and Sonveaux, 1987). Additionally, four Support Protocols
describe the preparation of the starting N-protected-2′-O-MTHP-ribonucleosides, which
are not commercially available and are considered key intermediates for the preparation
of the 5′-O-FMOC-protected ribonucleoside building blocks.
Characterization of the various products requires experience in thin-layer chromatogra-
phy, short column (flash) chromatography, and proton NMR.
BASIC
PROTOCOL
ACYLATION OF THE 5′-HYDROXY GROUP OF
2′-O-(4-METHOXYTETRAHYDROPYRAN-4-YL)-RIBONUCLEOSIDES
WITH 9-FLUORENYLMETHOXYCARBONYL CHLORIDE
The procedure describes the acylation of the 5′-hydroxy function of N-base- and 2′-O-
protected ribonucleosides with 9-fluorenylmethoxycarbonyl (FMOC) chloride in pyri-
dine at moderately low temperature. The FMOC workup procedure and the
chromatographic isolation and 1H-NMR spectroscopic characterization of the resulting
5′-O-(9-fluorenylmethyl)carbonates S.2a to S.2e (Fig. 2.4.1) are presented in this proto-
col. The starting intermediates are the four 2′-O-MTHP-protected ribonucleotides
rUMTHP, rCBzMTHP, rABzMTHP, and rGi-BuMTHP (S.1a to S.1d; Fig. 2.4.1 and Fig. 2.4.2) and
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deoxythymidine (dT; S.1e; Fig. 2.4.1). Support Protocols 1 to 4 provide a summary for
the preparation of the starting key intermediates S.1a to S.1d.
Materials
2′-Deoxythymidine or 2′-O-MTHP-ribonucleoside:
2′-O-(4-methoxytetrahydropyran-4-yl)-rU, -rCBz, -rABz, or -rGi-Bu (see Support
Protocols 1 to 4)
Dry pyridine, freshly distilled from calcium hydride (5 g/L) after refluxing for 2 hr
under an inert atmosphere
Nitrogen gas
9-Fluorenylmethoxycarbonyl (FMOC) chloride (Cambridge Research
Biochemicals), recrystallized from ether/pentane in a large desiccator (vapor
diffusion method)
Diethyl ether (analytical grade)
Chloroform stabilized with 1% ethanol (commercially available analytical grade)
Methanol (analytical grade)
Anisaldehyde reagent (see recipe)
Ethane-1,2-diol (analytical grade)
Saturated aqueous sodium bicarbonate solution
Sodium sulfate (anhydrous)
Toluene (analytical grade)
Ethanol (analytical grade)
Pentane (analytical grade)
Silica-coated thin-layer chromatography (TLC) plate with fluorescent indicator
Kieselgel 60F254 (Merck 5554 glass plates or 5744 aluminium foils)
UV light source
D4 glass-filter crucible
Short column (diameter 5 cm; length ~10 cm) containing 50 g Kieselgel 60H
without calcium sulfate (Merck 7736 or Fluka 60770, particle size 5-40 µm; or
Merck 11677, particle size 15 µm), preconditioned with chloroform
Glass-fiber tissue
CAUTION: Wear gloves and perform all operations involving TLC solvents and reagents
in a well-ventilated fume hood.
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Figure 2.4.1 General procedure for the preparation of 5′-O-fluorenylmethoxycarbonyl-2′-O-(4-
methoxytetrahydropyran-4-yl)-ribonucleosides (S.2a-d) and of 5′-O-fluorenylmethoxycarbonyl-2′-
deoxythymidine (S.2e).
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Introduce FMOC group
1. Coevaporate 3.0 mmol of 2′-O-MTHP-ribonucleoside or deoxythymidine derivative
(S.1a to S.1e) twice from 25 mL dry pyridine under reduced pressure using a rotary
evaporator, and then apply a dry nitrogen atmosphere.
2. Dissolve the substrate in a third 25-mL portion of dry pyridine and cool to 0°C.
3. Stir the solution and add 3.6 mmol crystalline FMOC chloride. Stir under nitrogen
for 30 min at 0°C.
Normally, all the FMOC chloride will have dissolved by this time.
Check reaction by TLC
4. Resolve products on a silica-coated TLC plate with fluorescent indicator. Develop
with diethyl ether followed by 9:1 (v/v) chloroform/methanol.
Predevelopment in diethyl ether is used to disperse the pyridine.
5. Visualize under UV light (254 nm).
6. Stain by spraying with anisaldehyde reagent and heating on a hot plate at 80°C.
Coloring plates containing nucleoside materials (summarized in Jork et al., 1990) is
necessary for compounds that do not absorb strongly in the 254-nm region (i.e., unprotected
rUMTHP and dT).
TLC shows complete conversion into products with higher Rf values than the starting
nucleosides. The major component is the 5′-O-FMOC derivative (see respective Rf valuesfor each nucleoside following step 18; when starting with S.1b, the 5′-derivative Rf = 0.54).
A very minor component at slightly higher Rf is identified as the 3′-O-FMOC derivative
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Figure 2.4.2 2′-O-(4-Methoxytetrahydropyran-4-yl)-ribonucleosides used as starting intermedi-
ates for FMOC protection. Preparation of these intermediates is shown in Figures 2.4.3 to 2.4.6.
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(Rf = 0.68 when starting with S.1b). Some 3′,5′-di-O-FMOC derivative can be found at a
very much higher Rf (0.80 when starting with S.1b).
If complete conversion is not observed, the reaction in step 3 can be continued. It should
not exceed 2 hr, however, as this leads to increased production of the 3′,5′-di-O-FMOC
derivative.
Isolate product by chromatography
7. Terminate the reaction by adding 200 µL of ethane-1,2-diol and concentrate the
mixture to an oil using a rotary evaporator with a vacuum pump.
8. Dissolve the oil in 150 mL chloroform and wash with 50 mL saturated aqueous
sodium bicarbonate solution. Remove the aqueous phase and wash twice with 50 mL
chloroform.
9. Dry the combined chloroform extracts over ~20 g anhydrous sodium sulfate.
10. Filter the dried extract under vacuum with a D4 glass filter crucible, and concentrate
under reduced pressure (step 7).
11. Coevaporate the residual oil from ∼50 mL each toluene (twice), ethanol (once), and
chloroform (once).
This removes traces of pyridine that are still contained in the dried, concentrated extract
(step 10).
12. Apply as concentrated as possible (i.e., in ∼5 mL) to a short 50-g Kieselgel 60H
column preconditioned with chloroform. Apply a circular piece of glass-fiber tissue
(not sea sand) to the top of the column.
Short-column chromatography is performed according to Hunt and Rigby (1967) and is
similar to the flash chromatography described by Still et al. (1978).
13. Elute minor side products first with chloroform (first 1 to 2 column volumes; 20-mL
fraction size), then elute the major product-containing fractions with a gradient of
1% to 5% (v/v) ethanol/chloroform. Do not use >1 atm pressure for elution (Hunt
and Rigby, 1967; Still et al., 1978).
14. Combine the product-containing fractions and concentrate to a foam.
15. Dissolve foam in 5 mL chloroform, precipitate by dropwise addition to 500 mL
rapidly stirring pentane, and decant off most of the supernatant (∼450 mL).
16. Collect solids by centrifuging 10 min at 3000 rpm g, 15°C, and decant the pentane.
17. Wash twice by resuspending in 50 mL fresh pentane and repeating the centrifugation.
Dry the resulting white powder (S.2a to S.2e) in vacuo using a high vacuum from an
oil pump.
Characterize the product
18. Characterize the final product by TLC and 1H-NMR.
Chemical characterization data is provided below for S.2a to S.2e. 1H-NMR spectra (250
MHz) were measured on a Bruker WM 250 instrument in DMSO-d6. Chemical shifts (δ)
are given in ppm downfield from tetramethylsilane (TMS, 0 ppm). Coupling constants (J)
are given in Hz. D2O exchange was performed on all samples.
5′-O-FMOC-2′-O-MTHP-uridine (S.2a): yield 64%; Rf (silica, chloroform/methanol 9:1):
0.43; 1H-NMR (250 MHz, DMSO-d6): 1.6-1.9 (m×m, 4H; -CH2-(3,5) of MTHP), 2.98 (s,
3H; H3CO- of MTHP), 3.3-3.7 (m×m, 4H; -CH2-(2,6) of MTHP), 3.9-4.6 (m×m, 8H;
-CH-(4′, 3′, 2′), -CH2-(5′), fluorenyl-H9 and -CH2-), 5.4 (dbr, 1H, exchangeable with D2O;
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3′-OH), 5.63 (d, J = 8.0 , 1H; uridyl-H5), 5.99 (d, J = 6.3, 1H; -CH-(1′)), 7.29-7.95 (m×m,
9H; uridyl-H6, fluorenyl-aromatic H), 11.4 (sbr, 1H, exchangeable; uridyl-N3-H).
5′-O-FMOC-2′-O-MTHP-4-N-benzoyl-cytidine (S.2b): yield 61%; Rf (silica, chloro-form/methanol 9:1): 0.54; 1H-NMR (250 MHz, DMSO-d6): 1.5-1.9 (m×m, 4H; -CH2-(3,5)
of MTHP), 2.95 (s, 3H; H3CO- of MTHP), 3.2-3.7 (m×m, 4H; -CH2-(2,6) of MTHP),
4.00-4.35 (m×m, 5H; -CH-(4′, 3′, 2′), -CH2-(5′)), 4.47 (t, J = 6.0, 1H; fluorenyl-H9), 4.54
(d, J = 6.0, 2H; fluorenyl-CH2-), 5.4 (d, J = 5, 1H, exchangeable with D2O; 3′-OH), 6.09
(d, J = 6.4, 1H; -CH-(1′)), 7.3-8.3 (m×m, 15H; cytidyl-H5 and -H6, fluorenyl- and
benzoyl-aromatic H), 11.3 (sbr, 1H, exchangeable; cytidyl-N4-H).
5′-O-FMOC-2′-O-MTHP-6-N-benzoyl-adenosine (S.2c): yield 65%; Rf (silica, chloro-form/methanol 9:1): 0.56; 1H-NMR (250 MHz ,DMSO-d6): 1.4-1.9 (m×m, 4H; -CH2-(3,5)
of MTHP), 2.62 (s, 3H; H3CO- of MTHP), 3.2-3.7 (m×m, 4H; -CH2-(2,6) of MTHP),
4.18-4.48 (m×m, 4H; -CH-(4′, 3′), -CH2-(5′)), 4.30 (t, J = 6.0, 1H; fluorenyl-H9), 4.51 (d,
J = 6.0, 2H; fluorenyl-CH2-), 5.08 (d×d, J2′-1′ = 6.8, J2′-3′ = 5.0; 1H; -CH-(2′)), 5.6 (d, J =
4.5, 1H, exchangeable with D2O; 3′-OH), 6.21 (d, J = 6.8, 1H; -CH-(1′)), 7.2-8.4 (m×m,
13H; fluorenyl- and benzoyl-aromatic H), 8.73 and 8.74 (2s, 2H; adenyl-H2 and H8), 11.3
(sbr, 1H, exchangeable; adenyl-N6-H).
5′-O-FMOC-2′-O-MTHP-2-N-isobutyryl-guanosine (S.2d): yield 52%; Rf (silica, chloro-form/methanol 9:1): 0.37; 1H-NMR (250 MHz, DMSO-d6): 1.12 (2d, J = 7.0, 6H;
(H3C)2CH-)), 1.4-1.9 (m×m, 4H; -CH2-(3,5) of MTHP), 2.67 (s, 3H; H3CO- of MTHP),
2.75 (septet, J = 7.0, 1H; (H3C)2CH-)), 3.2-3.7 (m×m, 4H; -CH2-(2,6) of MTHP), 4.12-4.37
(m×m, 4H; -CH-(4′, 3′), -CH2-(5′)), 4.34 (m(t), 1H; fluorenyl-H9), 4.53 (d, J = 6.0, 2H;fluorenyl-CH2-), 4.81 (d×d, J2′-1′ = 7.5, J2′-3′ = 4.7, 1H; -CH-(2′)), 5.4 (d, J = 4, 1H,
exchangeable with D2O; 3′-OH), 5.99 (d, J = 7.5, 1H; -CH-(1′)), 7.2-8.0 (m×m, 8H;fluorenyl-aromatic H), 8.25 (s, 1H; guanyl-H8), 11.6 and 12.1 (2sbr, 2H, exchangeable;
guanyl-N1-H and N2-H).
5′-O-FMOC-2′-deoxythymidine (S.2e): obtained in analytically pure form by subsequent
crystallization from ethyl acetate (76%; mp. 183°-185°C (decomp.); calc.: C 64.65, H 5.21,
N 6.03%; found: C 64.54, H 5.09, N 5.82%); Rf (silica, chloroform/methanol 9:1): 0.44;
1H-NMR (250 MHz, DMSO-d6): 1.69 (s, 3H; thymidyl-5-CH3), 2.10 (m, 2H; -CH2-(2′)),
3.90 (m, 1H; fluorenyl-H9), 4.10-4.40 (m×m, 4H; -CH-(4′, 3′), -CH2-(5′)), 4.58 (m(d), 2H;fluorenyl-CH2-), 5.44 (d, J = 4.4, 1H, exchangeable with D2O; 3′-OH), 6.17 (t, J = 6.3,
1H; -CH-(1′)), 7.29-7.91 (m×m, 9H; thymidyl-H6, fluorenyl-aromatic H), 11.3 (sbr, 1H,
exchangeable; thymidyl-N3-H).
SUPPORT
PROTOCOL 1
PREPARATION OF 2′-O-(4-METHOXYTETRAHYDROPYRAN-4-YL)-
URIDINE (S.1a) FROM URIDINE
Starting from uridine (S.3; Fig. 2.4.3), the desired key intermediate S.1a is obtained by a
series of well-described reactions that handle the three ribonucleoside hydroxy groups
differentially without protection of the base (Fromageot et al., 1967; Reese et al., 1970;
van Boom and Wreesmann, 1984). Chromatography is necessary only in the last step of
the sequence, which makes the procedure particularly useful for the preparation of large
amounts of material. In the first step, reaction of uridine (S.3) with trimethyl orthoacetate
gives the 2′,3′-methoxyethylidene derivative S.4, which is then acylated at the 5′-OH
group to yield S.5. This derivative is cleaved by partial acidic hydrolysis to give a mixture
of 2′,5′-di-O- and 3′,5′-di-O-acetates, of which the latter (S.6) can be fractionally
crystallized in good yield. Acid-catalyzed ketalization with 5,6-dihydro-4-methoxy-2H-
pyran followed by ammonolysis subsequently gives 2′-O-MTHP-uridine (S.1a).
Additional Materials (also see Basic Protocol)
Uridine (Sigma or Fluka), dried before use for 2 hr at 50°C over phosphorus
pentoxide in vacuo
Toluene-p-sulfonic acid monohydrate (analytical grade)
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Dioxane (analytical grade), dried by keeping over activated basic aluminum oxide,
then distilled before use from sodium/benzophenone after refluxing until the
blue color indicates complete dryness
Trimethyl orthoacetate (purum, 97%), dried by refluxing over calcium hydride (5
g/L) and distilled under inert atmosphere
Pyridine (analytical grade), dried by refluxing over calcium hydride (5 g/L) and
then distilled under inert atmosphere
Acetic anhydride (analytical grade)
Methylene chloride (analytical grade)
Saturated (~1 M) aqueous sodium hydrogen carbonate
Magnesium sulfate
Formic acid (analytical grade)
5,6-Dihydro-4-methoxy-2H-pyran (analytical grade; Sigma or Fluka pract., ~90%;
b.p.20 59° to 61°C)
Half-saturated methanolic ammonia solution (see recipe)
500-mL separatory funnel
Prepare 2′,3′-methoxyethylidene derivative (S.4)
1. Prepare a mixture of 
24.2 g dry uridine (S.3; 100 mmol)
100 mg toluene-p-sulfonic acid monohydrate
150 mL dry dioxane
17 mL dry trimethyl orthoacetate
and stir for 6 hr at room temperature.
2. Check the reaction by TLC (see Basic Protocol, steps 4 to 6).
TLC should show complete conversion of the starting material (Rf = 0.04) to the less polar
cyclic orthoester S.4 (Rf = 0.38).
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Figure 2.4.3 Scheme showing the preparation of 2′-O-MTHP-uridine (S.1a) from uridine (see
Support Protocol 1).
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Prepare 5′-acetylated derivative (S.5)
3. Combine 150 mL dry pyridine and 50 mL acetic anhydride. Add this acylating
solution dropwise over 15 min at room temperature to the stirred reaction mixture
(step 1), and leave overnight.
4. Check the reaction by TLC.
TLC should show that the acetylation has gone to completion to yield a product (S.5) with
higher mobility (Rf = 0.63).
5. Add 50 mL methanol dropwise to the reaction mixture at 0°C to destroy excess acetic
anhydride.
6. Concentrate the mixture to a colorless oil under reduced pressure using a rotary
evaporator.
7. Dissolve in 250 mL methylene chloride and wash with 100 mL of 1 M aqueous
sodium hydrogen carbonate.
8. Extract the aqueous layer five times with 100 mL methylene chloride for each
extraction.
9. Dry the combined organic layers over 25 g magnesium sulfate and concentrate to a
thick oil.
Prepare 3′,5′-di-O-acetyluridine (S.6)
10. Coevaporate the resulting oil twice from 100 mL ethanol to remove traces of pyridine.
11. Dissolve S.5 in 150 mL of 9:1 (v/v) formic acid/water and incubate 15 min at room
temperature.
12. Check the reaction by TLC.
TLC should show that the cleavage of the methoxyethylidene function is complete, yielding
2′,5′-di-O- and 3′,5′-di-O-acetyluridines (Rf  ≈ 0.4).
13. Evaporate the aqueous formic acid under reduced pressure with a rotary evaporator,
and coevaporate the residue twice with 100 mL toluene and twice with 100 mL
ethanol.
14. Dissolve in 250 mL chloroform and transfer to a 500-mL separatory funnel contain-
ing 150 mL saturated aqueous sodium hydrogen carbonate solution. Shake carefully
and separate out the chloroform layer.
15. Extract the aqueous layer twelve times with 50-mL portions of chloroform.
16. Dry the combined chloroform extracts over ~80 g anhydrous sodium sulfate, filter
(see Basic Protocol, step 10), and evaporate to a glass.
17. Dissolve the crude product in 500 to 1000 mL boiling ethanol and store the solution
for 2 days at room temperature.
18. Filter off the crystals and dry at high vacuum.
19. Determine the isomeric purity by 1H-NMR spectroscopy. Recrystallize the product
if the 2′,5′-isomer is present.
3′,5′-Di-O-acetyluridine (S.6): yield 23.9 g (73% from S.3; m.p. = 152°-155°C); Rf (silica,
chloroform/methanol 9:1): 0.42; 1H-NMR (250 MHz, DMSO-d6 /D2O, 1:1, containing
three drops of acetic acid per mL): 7.57 (d, J = 7.5, 1H; uridyl-H6), 5.89 (d, J = 7.5, 1H;
uridyl-H5), 5.88 (d, J = 5.5, 1H; -CH-(1′)); the 2′,5′-isomer shows a slightly different
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1H-NMR spectrum (same conditions): 7.57 (d, J = 7.5, 1H; uridyl-H6), 5.89 (d, J = 7.5,
1H; uridyl-H5), 5.86 (d, J = 6.0, 1H; -CH-(1′)).
Prepare 2′-O-MTHP-uridine (S.1a)
20. Combine 138 mg toluene-p-sulfonic acid monohydrate and 250 mL dry dioxane and
stir until clear.
21. Add 32.8 g of 3′,5′-di-O-acetyluridine (S.6; 100 mmol) and 57 g of 5,6-dihydro-
4-methoxy-2H-pyran (57 g, 5.0 eq) to the mixture and stir for 20 hr at room
temperature.
22. Check the reaction by TLC.
TLC should indicate complete reaction of the starting material.
23. Cool the clear solution in an ice water bath.
The solution should be below 0°C to absorb exothermicity during neutralization.
24. Neutralize the reaction mixture by adding 800 µl of half-saturated methanolic
ammonia solution.
25. Concentrate under reduced pressure and redissolve in 500 mL methanolic ammonia.
Let stand overnight and check the reaction by TLC.
TLC should show complete deacetylation.
26. Evaporate off methanolic ammonia and apply the residue to a column of silica gel
(300 g; 12 × 7 cm) packed in methylene chloride.
Short-column chromatography is performed according to Hunt and Rigby (1967) and is
similar to the flash chromatography described by Still et al. (1978). Do not use air pressure
>1 atm.
27. Elute the column with the following methylene chloride/methanol solutions: 500
mL of 98:2 (v/v); 500 mL of 96:4 (v/v); 1000 mL of 9:1 (v/v); and 1000 mL of
8:2 (v/v). Combine the product-containing fractions and evaporate to a colorless
glass.
28. Dissolve the residue in 25 mL chloroform, precipitate by dropwise addition to
2500 mL rapidly stirring pentane, and decant off most of the supernatant (>2000
mL).
29. Collect solids by centrifuging 10 min at 3000 rpm, 15°C, and decant the pentane.
30. Wash twice by resuspending in 250 mL fresh pentane and repeating the centrifuga-
tion. Dry the resulting white powder (S.1a) in vacuo.
31. Characterize the final product by TLC and 1H-NMR.
2′-O-MTHP-uridine (S.1a): yield 26.1 g (73% from S.6); Rf (silica, chloroform/methanol
9:1): 0.24; 1H-NMR (250 MHz, DMSO-d6): 1.50-1.90 (m×m, 4H; -CH2-(3,5) of MTHP),
2.95 (s, 3H; H3CO- of MTHP), 3.35-3-50 (m, 2H, -CH2-(5′)), 3.5-3.8 (m×m, 4H; -CH2-(2,6)
of MTHP), 3.90 (m, 1H; -CH-(4′)), 3.96 (m, 1H, -CH-(3′)), 4.25-4.36 (m, 1H; -CH-(2′)),
5.10-5.25 (d×tbr, 2H, exchangeable with D2O; 3′/5′-OH), 5.73 (d, J = 8.1, 1H; uridyl-H5),
6.00 (d, J = 7.8, 1H; -CH-(1′)), 7.93 (d, 1H; uridyl-H6), 11.4 (sbr, 1H, exchangeable;
uridyl-N3-H).
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SUPPORT
PROTOCOL 2
PREPARATION OF 2′-O-(4-METHOXYTETRAHYDROPYRAN-4-YL)-
4-N-BENZOYLCYTIDINE (S.1b) FROM CYTIDINE
In the first step of this procedure, cytidine (S.7; Fig. 2.4.4) is simultaneously protected
on its 3′- and 5′-hydroxy groups by the bifunctional protecting reagent 1,3-dichloro-
1,1,3,3-disiloxane (Markiewicz and Wiewerowski, 1985). The derivative S.8 is formed
exclusively, due to the higher reactivity of the sterically more accessible 5′-hydroxy group
and the subsequently favorable cyclization to the 3′-hydroxy group. Selective benzoyla-
tion on N4 of the base is then achieved by treatment with the active ester 1-hydroxyben-
zotriazolyl benzoate to give S.9. The latter compound is ketalized at the 2′-hydroxy group
upon reaction with 5,6-dihydro-4-methoxy-2H-pyran. Then a solution of n-tetrabutylam-
monium fluoride in acetonitrile removes the disiloxane protecting group to give 2′-O-
MTHP-4-N-benzoylcytidine (S.1b) in good yield (cf. Reese et al., 1970; van Boom and
Wreesmann, 1984). Chromatography is required only for the last step of the sequence.
Additional Materials (also see Basic Protocol and Support Protocol 1)
Cytidine (S.7; Sigma or Fluka), dried before use for 2 hr at 50°C over phosphorus
pentoxide in vacuo
N,N-Dimethylformamide, dried by stirring overnight at room temperature with
calcium hydride (5 g/L) and subsequent distillation under reduced pressure (b.p.
70° to 80°C, 20 to 30 mmHg)
Dry pyridine (see Support Protocol 1 for drying procedure)
1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane (see Support Protocol 5)
2 M triethylammonium bicarbonate buffer (see recipe)
Acetone (analytical grade)
1-Hydroxybenzotriazole (Fluka), dried before use for 72 hr at 50°C over
phosphorus pentoxide in vacuo
Triethylamine, dried by refluxing 2 hr over calcium hydride (5 g/L) followed by
distillation
Benzoyl chloride (Fluka, puriss.)
Acetonitrile (analytical grade)
1 M n-tetrabutylammonium fluoride (Aldrich/Fluka) in acetonitrile
CAUTION: 1-Hydroxybenzotriazole may explode at higher temperatures.
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Figure 2.4.4 Scheme showing the preparation of 2′-O-MTHP-4-N-benzoylcytidine (S.1b) from
cytidine (see Support Protocol 2).
Current Protocols in Nucleic Acid Chemistry
2.4.9
Protection of
Nucleosides for
Oligonucleotide
Synthesis 
Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)cytidine (S.8)
1. Prepare and stir a suspension of the following:
12.12 g dry cytidine (S.7; 50 mmol)
200 mL dry N,N-dimethylformamide
40 mL dry pyridine (40 mL).
2. Add 18 mL of 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (62.5 mmol) to 50 mL
dry N,N-dimethylformamide and add dropwise to the stirred cytidine solution over a
period of 15 min. Stir the reaction mixture for 1 hr at room temperature.
3. Check the reaction by TLC (see Basic Protocol, steps 4 to 6).
TLC should indicate complete reaction of the starting material (Rf < 0.05) to S.8 (Rf =
0.28).
4. Neutralize with 75 mL of 2 M triethylammonium bicarbonate buffer and concentrate
under reduced pressure to a small volume (100 mL) using a rotary evaporator.
5. Dissolve in 1000 mL methylene chloride and wash with 500 mL of 1 M aqueous
sodium hydrogen carbonate followed by 500 mL water.
6. Dry the organic layer over 50 g magnesium sulfate and concentrate to a colorless oil.
7. Crystallize from 500 mL acetone to produce pure 3′,5′-O-(tetraisopropyldisiloxane-
1,3-diyl)cytidine.
3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)cytidine (S.8): yield 19.5 g (85%), m.p. 226-228
(decomp.), Rf = 0.28. 1H-NMR (CDCl3/CD3OD): 8.00 (d, J = 7.5, 1H; cytidyl-H6), 7.58
(d, J = 7.5, 1H; cytidyl-H5), 5.64 (d, J = 5.5, 1H; -CH-(1′)); 13C-NMR (CDCl3/CD3OD):
166.2 (C4), 156.3 (C2), 140.6 (C6), 94.7 (C5), 91.5 (C1′), 81.6 (C4′), 75.1 (C3′), 68.2 (C2′),
60.0 (C5′), 17.4, 17.0 13.5, 13.0, 12.5 (TIPS).
Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-4-N-benzoyl-cytidine (S.9)
8. Prepare and stir a solution of the following:
10.0 g dry 1-hydroxybenzotriazole (75 mmol)
300 mL dry dioxane
21 mL dry triethylamine (150 mmol).
9. Combine 8.70 mL benzoyl chloride (75 mmol) and 50 mL dry dioxane, and add
dropwise to the above mixture (step 8) over 15 min. Stir for 1 hr at room temperature.
10. Filter off the precipitated triethylammonium chloride salts under inert atmosphere
using a glass filter crucible, and add the filtrate to a solution containing 24.25 g of
2′-O-(tetraisopropyldisiloxane-1,3-diyl)cytidine (S.8; 50 mmol) in 150 mL dry N,N-
dimethylformamide.
11. Evaporate off a volume of ∼100 mL under reduced pressure and stir the residue at
room temperature for 3 days. Check the reaction by TLC.
TLC should indicate complete reaction of the starting material.
12. Add 5 mL water and concentrate the reaction mixture under reduced pressure to a
small volume (100 mL).
13. Dissolve in 1000 mL methylene chloride and wash as in step 5.
14. Dry the organic layer over 50 g magnesium sulfate and concentrate to a light brown
oil.
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15. Crystallize from a minimal amount of refluxing acetonitrile to yield analytically pure
3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-4-N-benzoylcytidine (S.9).
3′,5′-O-(Tetraisopropyldisiloxane-1,3-diyl)-4-N-benzoylcytidine (S.9): yield 22.6 g (77%
in first crop). Rf = 0.40 (silica, chloroform/methanol 9:1). Elemental analysis: calc.; C
57.04, H 7.30, N 7.26%; found: C 56.36, H 7.08, N 7.26%.
Prepare 2′-O-MTHP-4-N-benzoylcytidine (S.1b)
16. Dissolve 4.75 g toluene-p-sulfonic acid monohydrate (25 mmol) in 125 mL dry
dioxane and evaporate under reduced pressure to a colorless oil to remove traces of
water.
17. Under an inert atmosphere, add 29.45 g of 3′,5′-O-(tetraisopropyldisiloxane-1,3-
diyl)-4-N-benzoylcytidine (S.9; 50 mmol) followed by 250 mL dry dioxane.
18. To the resulting clear solution, add 29 mL of 5,6-dihydro-4-methoxy-2H-pyran (28.5
g; 250 mmol). Stir 20 hr at room temperature and check the reaction by TLC.
TLC should show complete reaction of the starting material.
19. Neutralize the reaction with 3.5 mL half-saturated methanolic ammonia solution
(check with moist pH indicator paper) and concentrate immediately under reduced
pressure to a small volume (100 mL).
20. Dissolve in 1000 mL methylene chloride and wash as in step 5.
21. Dry the organic layer over 50 g magnesium sulfate and concentrate to a glass.
22. Add 250 mL of 1 M n-tetrabutylammonium fluoride in acetonitrile, stir for 1 hr at
room temperature, and check the reaction by TLC.
TLC should show complete removal of the silyl protecting group.
n-Tetrabutylammonium fluoride in acetonitrile must be prepared by the experimenter.
Commercially available solutions in tetrahydrofuran can also be used.
23. Concentrate under reduced pressure to a small volume (100 mL). Dissolve in
methylene chloride, wash, and dry as in steps 20 and 21.
24. Dissolve with a minimal amount of dichloromethane and apply to a column of silica
gel (300 g; 12 × 7 cm) packed in methylene chloride.
Short-column chromatography is performed according to Hunt and Rigby (1967) and is
similar to the flash chromatography described by Still et al. (1978). Do not use air pressure
>1 atm.
25. Elute the column with the following methylene chloride/methanol solutions: 500 mL
of 98:2 (v/v); 500 mL of 96:4 (v/v); and 1000 mL of 9:1 (v/v).
26. Collect the main product-containing fractions and evaporate to a glass.
27. Dissolve the residue in 25 mL chloroform, precipitate by dropwise addition to 2500
mL rapidly stirring pentane, and decant off most of the supernatant (>2000 mL).
28. Collect the solids by centrifuging 10 min at 3000 rpm g, 15°C, and decant the pentane.
29. Wash twice by resuspending in 250 mL fresh pentane and repeating the centrifuga-
tion. Dry the resulting white powder (S.1b) in vacuo.
30. Characterize the final product by TLC and 1H-NMR.
2′-O-MTHP-4-N-benzoylcytidine (S.1b): yield 16.1 g (70% from S.9); Rf (silica, chloro-form/methanol 9:1): 0.43; 1H-NMR (250 MHz, DMSO-d6): 1.50-1.90 (m×m, 4H; -CH2-
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(3,5) of MTHP), 2.93 (s, 3H; H3CO- of MTHP), 3.40-3.60 (m, 2H, -CH2-(5′)), 3.5-3.8
(m×m, 4H; -CH2-(2,6) of MTHP), 3.96 (m, 1H; -CH-(4′)), 4.02 (m, 1H, -CH-(3′)), 4.39
(m(d×d), 1H; -CH-(2′)), 5.19 (d, J = 6.5, 1H, exchangeable with D2O; 3′-OH), 5.25 (t, J
= 2.7, 1H, exchangeable with D2O; 5′-OH), 6.14 (d, J = 6.8, 1H; -CH-(1′)), 7.36 (d, J =
7.7, 1H; cytidyl-H5), 7.4-8.1 (m×m, 5H; benzoyl-aromatic H), 8.43 (d, 1H; cytidyl-H6),
11.3 (sbr, 1H, exchangeable with D2O; cytidyl-N4-H).
SUPPORT
PROTOCOL 3
PREPARATION OF 2′-O-(4-METHOXYTETRAHYDROPYRAN-4-YL)-
6-N-BENZOYLADENOSINE (S.1c) FROM ADENOSINE
In this protocol, adenosine (S.10, Fig. 2.4.5) is base protected prior to 3′,5′-disilylation
by benzoylation of its crystalline 2′,3′,5′-tri-O-acetyl-derivative (S.11), yielding 6-N-ben-
zoyladenosine (S.12) after deacetylation in situ. The chosen route (cf. Schaller et al., 1963;
Reese et al., 1970; Büchi and Khorana, 1972; Jones, 1984; van Boom and Wreesmann,
1984; Markiewicz and Wiewerowski, 1985) is then comparable to the cytidine case (see
Support Protocol 2): 3′,5′-disilylation to yield S.13, followed by acid-catalyzed ketaliza-
tion of the 2′-OH by 5,6-dihydro-4-methoxy-2H-pyran, and cleavage of the silyl protect-
ing group by fluoride ion to yield 2′-O-MTHP-6-N-benzoyladenosine (S.1c) in good
chromatographically isolated yield.
Additional Materials (also see Basic Protocol and  Support Protocols 1 and 2)
Adenosine (S.10; Sigma or Fluka), dried before use for 2 hr at 50°C over
phosphorus pentoxide in vacuo
Dry pyridine (see Support Protocol 1 for drying procedure)
Acetic anhydride, fractionally distilled with 10% toluene to remove acetic acid
25% (w/v) sodium methoxide in methanol (pract., Aldrich, Fluka)
Acetic acid (analytical grade)
Diethyl ether (analytical grade)
Imidazole (analytical grade)
0.1 M hydrochloric acid
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Figure 2.4.5 Scheme showing the preparation of 2′-O-MTHP-6-N-benzoyladenosine (S.1c) from
adenosine (see Support Protocol 3). The final step from S.13 to S.1c is performed as in steps 16 to
30 of Support Protocol 2 (see Fig. 2.4.4).
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Prepare 2′,3′,5′-tri-O-acetyladenosine (S.11)
1. Prepare and stir a suspension of 10.0 g adenosine (S.10; 37.4 mmol) in 50 mL dry
pyridine.
2. Add 23 mL acetic anhydride (0.24 mol) and stir overnight at room temperature.
3. Cool in an ice bath and quench with 40 mL methanol.
4. Remove from the ice bath and stir 1 hr at room temperature.
5. Concentrate to dryness, and recrystallize the white solid residue twice from 100 mL
hot ethanol to yield 12.0 g (82%) tri-O-acetyladenosine (S.11). Check the product by
TLC (see Basic Protocol, steps 4 to 6).
The product is sufficiently pure (Rf = 0.31) for use in the subsequent steps.
Prepare 6-N-benzoyladenosine (S.12)
6. Dissolve crystalline S.11 in 50 mL pyridine, cool in an ice bath, and add 5.3 mL
benzoyl chloride (45.8 mmol).
7. Let the reaction mixture warm to room temperature and stir for 2 hr.
8. Quench with 6 mL water and stir for another 30 min.
9. Concentrate to a syrup using a rotary evaporator.
10. Partition the residue between 100 mL chloroform and 100 mL saturated aqueous
sodium hydrogen carbonate solution. Reextract the aqueous phase with two 50-mL
portions of chloroform.
11. Dry the combined organic extracts over ~20 g anhydrous sodium sulfate and evapo-
rate to a glass (Rf = 0.71).
12. Redissolve in 50 mL of 1:1 (v/v) methanol/pyridine, cool on ice, and then add 15 mL
(∼3 eq) of 25% sodium methoxide in methanol.
13. Let the reaction mixture warm to room temperature and monitor by TLC.
Deacetylation to the more polar product (Rf = 0.24) occurs in <15 min.
14. Neutralize with 4.0 mL acetic acid and evaporate to a small volume (~13) under reduced
pressure.
15. Pour the concentrated product mixture into 100 mL saturated aqueous sodium
hydrogen carbonate and extract with 200 mL chloroform.
16. Collect the precipitate that settles between the chloroform and aqueous layers by
centrifuging 10 min at 3000 rpm, 15°C.
17. Resuspend in ∼100 mL water and centrifuge again. Repeat with ∼100 mL each
ethanol and then diethyl ether.
18. Dry the white solid first in air and then under high vacuum to yield 7.15 g (63%) S.12
as a white solid. Check the product by TLC.
The product is sufficiently pure (Rf  = 0.24) for use in the subsequent steps.
Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-6-N-benzoyladenosine (S.13)
19. Dissolve 2.40 g of 6-N-benzoyladenosine (S.12; 6.46 mmol) in 32 mL dry pyridine.
20. Add 2.16 g imidazole followed by 2.50 mL of 1,3-dichloro-1,1,3,3-tetraisopropyldi-
siloxane (7.9 mmol; 1.2 eq).
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21. Stir the reaction overnight. Check the reaction by TLC.
TLC should show complete reaction of the starting material.
22. Add 10 mL methanol, stir for another 15 min, and concentrate under reduced pressure.
23. Take up the residue in 50 mL chloroform and wash sequentially with 25 mL saturated
sodium hydrogen carbonate solution, 50 mL of 0.1 M hydrochloric acid, and 30 mL
water.
24. Evaporate the organic layer.
25. Remove traces of pyridine by coevaporating with ∼50 mL (once each) toluene,
ethanol, and chloroform.
26. Purify the crude product by short-column chromatography (see Basic Protocol, step
12). Elute with chloroform until the product appears, then with chloroform containing
2% (v/v) ethanol (∼700 mL total in 20-mL fractions). Do not use >1 atm pressure for
elution (Hunt and Rigby, 1967; Still et al., 1978).
27. Combine the product-containing fractions, evaporate the solvent, and dry under high
vacuum to yield 3.21 g (81%) chromatographically pure S.13 as a colorless foam.
Check by TLC (Rf = 0.58).
Prepare 2′-O-MTHP-6-N-benzoyladenosine (S.1c)
28. Introduce the MTHP protecting group and perform desilylation (see Support Protocol
2, steps 16 to 30), replacing S.9 (29.45 g; 50 mmol) with the corresponding adenosine
derivative S.13 (30.84 g; 50 mmol) to yield S.1c as a dry white powder.
2′-O-MTHP-6-N-benzoyladenosine (S.1c): yield 18.9 g (78% from S.13); Rf (silica, chlo-
roform/methanol 9:1): 0.30; 1H-NMR (250 MHz, DMSO-d6): 1.40-1.90 (m×m, 4H; -CH2-
(3,5) of MTHP), 2.55 (s, 3H; H3CO- of MTHP), 3.20-3.80 (m×m, 2H, -CH2-(5′)), 3.3-3.8
(m×m, 4H; -CH2-(2,6) of MTHP), 4.05 (m, 1H; -CH-(4′)), 4.18 (m, 1H, -CH-(3′)), 5.00
(m(d×d), 1H; -CH-(2′)), 5.27 (t, J = 5.5, 1H, exchangeable with D2O; 5′-OH), 5.33 (d, J
= 4.5, 1H, exchangeable with D2O; 3′-OH), 6.19 (d, J = 7.4, 1H; -CH-(1′)), 7.5-8.1 (m×m,
5H; benzoyl-aromatic H), 8.77 (2s, 2H; adenyl-H2/8), 11.3 (sbr, 1H, exchangeable with
D2O; adenyl-N6-H).
SUPPORT
PROTOCOL 4
PREPARATION OF 2′-O-(4-METHOXYTETRAHYDROPYRAN-4-YL)-2-N-
ISOBUTYRYLGUANOSINE (S.1d) FROM GUANOSINE
Guanosine (S.14; Fig. 2.4.6) is base protected on N2 (S.16) by reaction with isobutyryl
chloride after transiently blocking the 2′-, 3′-, and 5′-hydroxy groups by persilylation
(S.15). The chosen route is then comparable to the cytidine and adenosine cases:
3′,5′-disilylation to S.17, followed by acid-catalyzed ketalization of the 2′-OH by 5,6-di-
hydro-4-methoxy-2H-pyran and cleavage of the silyl protecting group by fluoride ion to
yield 2′-O-MTHP-2-N-isobutyrylguanosine (S.1d) in satisfactory isolated yield. Gener-
ally, the higher basicity and polarity of guanosine derivatives renders them more difficult
to handle, and the yields are frequently compromised by loss of material in aqueous
extraction media or on polar silica gel phases. Nevertheless, the proposed sequence is a
viable route that is based on well-described literature procedures (Reese et al., 1970; Ti
et al., 1982; Jones, 1984; van Boom and Wreesmann, 1984; Markiewicz and Wiew-
erowski, 1985; McLaughlin et al., 1985).
Additional Materials (also see Basic Protocol and Support Protocols 1 and 2)
Guanosine (S.14; Sigma or Fluka), dried before use for 2 hr at 50°C over
phosphorus pentoxide in vacuo
Dry pyridine (see Support Protocol 1 for drying procedure)
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Trimethylsilyl chloride (analytical grade)
Isobutyryl chloride (analytical grade)
Concentrated aqueous ammonia (~25%)
Methylene chloride (analytical grade)
Phosphorus pentoxide
Prepare 2-N-isobutyrylguanosine (S.16)
1. Suspend 14.15 g dry guanosine (S.14; 50 mmol) in 200 mL dry pyridine.
2. Add 47.5 mL trimethylsilyl chloride (375 mmol) and stir for 3 hr at ambient
temperature to produce S.15.
3. Cool to 0°C and add 15.6 mL isobutyryl chloride (150 mmol), dropwise, over a period
of 30 min.
4. Allow to warm to room temperature and stir overnight.
5. Cool again to 0°C and quench by adding 50 mL water. Stir for another 10 min at room
temperature.
6. Add 100 mL concentrated aqueous ammonia to the clear solution and stir for an
additional 30 min.
7. Pour the mixture into 800 mL water and extract with 150 mL methylene chloride.
8. Evaporate the aqueous phase to dryness and crystallize three times from 50 to 100
mL boiling water.
9. Dry the resulting solids for 2 days under high vacuum over phosphorus pentoxide to
obtain 7.25 g (41%) 2-N-isobutyrylguanosine (S.16) as a grayish-white, chroma-
tographically homogenous powder. Check by TLC (see Basic Protocol, steps 4 to 6;
Rf = 0.074).
Prepare 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-2-N-isobutyrylguanosine (S.17)
10. Dissolve 7.05 g of 2-N-isobutyrylguanosine (S.16; 20.0 mmol) in 125 mL dry
pyridine.
11. Add 6.6 mL of 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (24 mmol) and stir
overnight. Check the reaction by TLC.
TLC shows complete reaction of the starting material.
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Figure 2.4.6 Scheme showing the preparation of 2′-O-MTHP-2-N-isobutyrylguanosine (S.1d)
from guanosine (see Support Protocol 4).
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12. Evaporate the suspension and partition between 250 mL chloroform and 250 mL
saturated aqueous sodium hydrogen carbonate solution.
13. Reextract the aqueous layer twice with 125 mL chloroform, dry the organic layer
over ~30 g sodium sulfate, and evaporate to a glass using a rotary evaporator.
14. Remove traces of pyridine by azeotropic rotoevaporation from 100 mL toluene
(twice), 100 mL ethanol (once), and 100 mL chloroform (once).
15. Purify the crude product by short-column chromatography using 200 g silica gel (see
Basic Protocol, step 12). Elute with chloroform until the product appears, then with
chloroform containing 2% (v/v) ethanol (∼1500 mL total in 30-mL fractions). Do not
use >1 atm pressure for elution (Hunt and Rigby, 1967; Still et al., 1978).
16. Combine the product-containing fractions, evaporate the solvent, and dry under high
vacuum to give 7.25 g (61%) chromatographically pure S.17 as a colorless foam.
Check by TLC (Rf = 0.55).
Prepare 2′-O-MTHP-2-N-isobutyrylguanosine (S.1d)
17. Dissolve 0.95 g of toluene-p-sulfonic acid monohydrate (5 mmol) in 25 mL dry
dioxane and evaporate under reduced pressure to a colorless oil to remove traces of
water.
18. Under an inert atmosphere, add 5.95 g of 3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)-
2-N-isobutyrylguanosine (S.17; 10 mmol) followed by 50 mL dry dioxane.
19. To the resulting clear solution, add 5.8 mL of 5,6-dihydro-4-methoxy-2H-pyran (5.7
g, 50 mmol). Stir 20 hr at room temperature and check the reaction by TLC.
TLC should show complete reaction of the starting material.
20. Neutralize the reaction with 0.8 mL half-saturated methanolic ammonia solution and
concentrate immediately under reduced pressure to a small volume (20 mL).
21. Dissolve the residue in 200 mL chloroform and wash with 100 mL of 1 M aqueous
sodium hydrogen carbonate solution.
22. Dry the organic layer over 50 g magnesium sulfate and concentrate to a glass.
23. Add 50 mL of 1 M n-tetrabutylammonium fluoride in acetonitrile, stir for 1 hr at
room temperature, and check the reaction by TLC.
TLC should show complete removal of the silyl group.
24. Concentrate under reduced pressure to a small volume (20 mL). Dissolve in chloro-
form and wash as in step 21.
25. Reextract the aqueous phase twice with 100 mL chloroform.
26. Dry the organic layer over 10 g anhydrous sodium sulfate and concentrate to a glass.
27. Dissolve the residue with minimal amount of chloroform and apply to a column of
silica gel (100 g; 8 × 5 cm) packed in chloroform.
28. Elute the column with chloroform until the product appears, and then collect 20-mL
fractions with the following chloroform/ethanol solutions: 300 mL of 98:2 (v/v); 300
mL of 96:4 (v/v), 600 mL of 9:1 (v/v).
29. Collect the main product-containing fractions and evaporate to a glass.
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30. Dissolve the residue in 25 mL chloroform, precipitate by dropwise addition to 500
mL rapidly stirring pentane, and decant off most of the supernatant (>400 mL).
31. Collect the solids by centrifuging 10 min at 3000 rpm, 15°C, and decant the pentane.
32. Wash the solids twice by resuspending in 100 mL fresh pentane and repeating the
centrifugation. Dry the resulting white powder (S.1d) in vacuo.
33. Characterize the final product by TLC and 1H-NMR.
2′-O-MTHP-2-N-isobutyrylguanosine (S.1d): yield 2.42 g (52% from S.17); Rf (silica,
chloroform/methanol 9:1): 0.29; 1H-NMR (250 MHz, DMSO-d6): 1.12 (2d, J = 6.8, 6H;
(H3C)2CH-)), 1.40-1.90 (m×m, 4H; -CH2-(3,5) of MTHP), 2.55 (s, 3H; H3CO- of MTHP),
2.75 (septet, J = 6.8, 1H; (H3C)2CH-)), 3.19-3.33 (m×m, 2H, -CH2-(5′)), 3.4-3.7 (m×m,
4H; -CH2-(2,6) of MTHP), 3.98 (m(t), 1H; -CH-(4′)), 4.10 (m(t), 1H, -CH-(3′)), 4.74
(m(d×d), 1H; -CH-(2′)), 5.77 (m(t), 1H, exchangeable with D2O; 5′-OH), 5.19 (m(d), 1H,
exchangeable with D2O; 3′-OH), 6.98 (d, J = 7.9, 1H; -CH-(1′)), 7.5-8.1 (m×m, 5H;
benzoyl-aromatic H), 8.31 (s, 1H; guanyl-H8), 11.7/12.1 (2sbr, 2H, exchangeable with
D2O; guanyl-N1-H and N2-H).
SUPPORT
PROTOCOL 5
PREPARATION OF 1,3-DICHLORO-1,1,3,3-
TETRAISOPROPYLDISILOXANE
Although this reagent is commercially available (e.g., Fluka), this protocol provides a
convenient procedure for its preparation.
Materials
Magnesium curls
Dry diethyl ether, distilled from phosphorus pentoxide (30 g/L)
Isopropyl bromide, distilled from calcium hydride (5 g/L)
Trichlorosilane, freshly distilled
0.1 N hydrochloric acid
Magnesium sulfate
Methylene chloride (analytical grade), dried by passage through activated basic
alumina
Chlorine gas, dried over concentrated sulfuric acid
NaCl plates for infrared (IR) spectroscopy
Additional reagents and equipment for IR spectroscopy
Prepare 1,1,3,3-tetraisopropyldisiloxane
1. Combine 64 g magnesium curls and 200 mL dry diethyl ether.
2. Add a solution of 270 mL isopropyl bromide in 400 mL dry diethyl ether dropwise
to the solution.
3. Stir the reaction mixture mechanically and heat under reflux for 3.5 hr.
4. Add a solution of 100 mL trichlorosilane and 400 mL dry diethyl ether dropwise to
the stirred solution (step 3) and heat under reflux overnight.
5. Quench by adding 800 mL of 0.1 N hydrochloric acid in a dropwise fashion.
6. Stir the mixture and heat under reflux for another 3.5 hr.
7. Separate out the organic layer and extract the aqueous layer three times with 300 mL
diethyl ether.
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8. Dry the combined organic layers over ~50 g magnesium sulfate and concentrate to a
colorless oil under reduced pressure.
9. Distill the residue to produce pure 1,1,3,3-tetraisopropyldisiloxane (100 g; b.p. 80°
to 90°C, 10 mmHg) as a colorless oil.
Prepare 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane
10. Dissolve the above product (100 g of 1,1,3,3-tetraisopropyldisiloxane) in 500 mL
methylene chloride and pass a stream of dry chlorine gas through the solution.
Protect the apparatus from atmospheric moisture using a paraffin oil bubbler. Calcium
chloride drying tubes are entirely inefficient and will lead to reaction  failure.
11. When the temperature rises to ∼27° to 30°C, cool the reaction mixture to 17° to 20°C
by immersing it in an ice water bath while continuing the stream of chlorine gas.
12. After 2 hr, and then after every hour, withdraw a small sample of the reaction mixture
and analyze by IR spectroscopy using NaCl plates.
13. Stop the chlorination when the IR spectrum indicates the disappearance of the
absorption band at 2100 cm−1 (Si-H).
14. Evaporate off the volatile compounds and distill the residue under diminished
pressure (b.p. 85° to 90°C, 2 mmHg) to give 1,3-dichloro-1,1,3,3-tetraisopropyldis-
iloxane (70 g) as a colorless oil. Store dry at 0°C for up to several months or even
years.
REAGENTS AND SOLUTIONS
Use distilled, deionized water for all recipes and protocol steps. For common stock solutions, see
APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Anisaldehyde reagent
1 mL 4-methoxybenzaldehyde
2 mL concentrated sulfuric acid
10 mL glacial acetic acid
87 mL methanol (analytical grade)
Store up to 6 months at room temperature
All analytical-grade reagents are preferred if available.
Methanolic ammonia solution, half-saturated (∼8 M)
Pass dry ammonia gas (passed over solid potassium hydroxide pellets) through 500
mL analytical-grade methanol at −20°C until saturation. Dilute with 500 mL
analytical-grade methanol. Store up to 4 weeks at –18°C.
Triethylammonium bicarbonate buffer, 2 M
Combine 825 mL analytical-grade triethylamine and 2175 mL water. Saturate with
carbon dioxide gas at 0°C until the pH of the clear solution reaches 7.5. Store up to
4 weeks at 4°C.
COMMENTARY
Background Information
Within the field of solid-phase peptide syn-
thesis, the introduction of a base-labile protect-
ing group for the nucleophilic (amino-) center
has been very successful, exceeding by far the
status of alternative and becoming a standard
technique in many laboratories (Atherton and
Sheppard, 1989, and references cited therein).
The base-sensitive amino-protecting 9-fluo-
renylmethoxycarbonyl (FMOC) group, first in-
troduced by Carpino and Han in 1970 (for a
review see Carpino, 1987), is strictly orthogo-
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nal to the acid-labile protecting groups used for
the side chains. Orthogonality is fulfilled when
permanent side-chain protecting groups remain
completely stable during peptide assembly
while being repeatedly exposed to the condi-
tions applied for removal of the temporary
terminal protecting group. For solid-phase oli-
gonucleotide assemblies, the use of 5′-O-
FMOC chemistry may provide an opportunity
for such orthogonality, and also avoids the
problem of depurination occasionally observed
during repeated acidolytic steps required for
5′-O-detritylation.
Compared to solid-phase peptide synthesis,
functional protection is less demanding in oli-
gonucleotide synthesis due to the smaller num-
ber of building blocks. In the deoxyribonu-
cleotide series, very satisfactory protecting
groups have resulted from the pioneering ef-
forts in the chemical synthesis of genes by the
group of Khorana (e.g., Schaller et al., 1963;
Büchi and Khorana, 1972). For example, per-
manent protection of the exocyclic amino func-
tions as N-acyl and N-aroyl derivatives, respec-
tively, is compatible with nonnucleophilic con-
ditions, but the protecting groups may be
cleaved at the very end of the synthesis by
hydrolysis in aqueous ammonium hydroxide at
elevated temperature.
On the other hand, an adequate treatment of
the protecting group strategy in RNA synthesis
requires the differential handling of the 2′-, 3′-,
and 5′-hydroxy groups. If phosphoramidite
chemistry is chosen for chain extension, the
central problem is the selection of a suitable
combination of the permanent 2′-hydroxyl-
protecting group together with a temporary
5′-hydroxyl-protecting group. The former must
remain intact until the very end of the synthesis,
including base deprotection, whereafter it must
be removed very cleanly and under conditions
that leave the phosphate-ribose backbone in
complete constitutional and regiochemical in-
tegrity. This was convincingly shown both for
the acetal (tetrahydropyranyl or THP) as well
as the presently applied 4-methoxytetrahy-
dropyranyl (MTHP) ketal-type of 2′-hydroxyl-
protecting groups some years ago by the re-
search group of Reese (Norman et al., 1984). It
was demonstrated by HPLC analysis that di-
uridine and diadenosine phosphates are stable
in 0.01 N hydrochloric acid for time periods
over ten times longer than that required for
complete 2′-deprotection. Moreover, the
authors (Christodoulou et al., 1986) and others
(Reese and Skone, 1985) showed that if a con-
ventional acid-labile group such as di-O-(p-an-
isyl)phenylmethyl (dimethoxytrityl or DMTr)
or 9-phenylxanthen-9-yl (pixyl or Px) is used
to protect the 5′ position, concomitant cleavage
of the 2′-O-THP or 2′-O-MTHP takes place to
an unacceptable extent. For orthogonal protec-
tion of the 5′-hydroxy group, the authors there-
fore chose the base-labile FMOC protecting
group (Fig. 2.4.1 and Fig. 2.4.7).
FMOC was first proposed for 5′-O-protec-
tion in the deoxyribonucleotide series for solid-
phase synthesis of an octathymidylic acid frag-
ment (Gioeli and Chattopadhyaya, 1982), and
was later used in the same laboratory for the
regioselective construction of a 2′-O-pixyl-
protected dinucleotide (Pathak and Chattopad-
hyaya, 1985). Later, the results reported for
oligothymidylic acids were extended to de-
oxyribonucleotide sequences containing 4-N-
benzoyl-2′-deoxycytidine and 6-N-benzoyl-2′-
deoxyadenosine, whereby the above procedure
for the regioselective introduction of the FMOC
group was again confirmed (Ma and Sonveaux,
1987; Balgobin and Chattopadhyaya, 1987).
An approach for a solution-phase RNA synthe-
sis combining an acid-labile acetal group (1-
ethoxyethyl) for 2′-protection with 5′-O-
FMOC was proposed by Fukuda et al. (1988).
However, the drawback of using chiral protect-
ing groups on chiral nucleoside building blocks
has been commented on with crystallographic
data (Lehmann et al., 1991).
Further efforts to incorporate the FMOC
strategy within the framework of solid-phase
O BO
O O
O
OCH3
[Mthp]
5'
3' 2'
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RO
N(i-Pr)2
B = U;
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5'-O-protection permanent
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2'-O-protection
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R = CH2CH2CN
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Figure 2.4.7 Orthogonal protection scheme
for solid-phase RNA synthesis applying a tem-
porary base-labile (FMOC) 5′-O-protecting
group and a permanent acid-labile (MTHP) 2′-
O-protecting group within the phosphoramidite
strategy. Compatibility with current variants of
phoshate internucleotide protection as well as
anchorage to the solid support are discussed
in the text.
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oligonucleotide chemistry were aimed at avoid-
ing unwanted side reactions during deprotec-
tion. Primarily, it was reported (Gao et al.,
1985) that, under strongly basic deprotection
conditions (5% 1,8-diazabicyclo-[5.4.0]undec-
7-ene [DBU] in acetonitrile), methyl group
transfer to the N3 position of thymine (and
presumably uracil) occurs via an intramolecu-
lar SN2-reaction from the phosphotriester link-
age if the common methyl phosphoramidite
chemistry is applied. It was not possible to use
H-phosphonates, since the latter are decom-
posed immediately under the action of base
(Lehmann et al., 1989). The authors therefore
first applied cyanoethyl phosphoramidites,
presently in use for DNA synthesis, conscious
of the fact that probably some or all of the
phosphate protection is lost during FMOC
cleavage. Nevertheless, the results were re-
markably encouraging, and it was possible to
assemble oligomers of up to 20 residues con-
taining all four ribonucleosides in good yield
and in regiochemically homogenous form.
The fact that phosphoramidite building
blocks are of a significantly basic nature and
are prone to hydrolysis to the corresponding
H-phosphonates on normal silica gel surfaces
demands deactivation of such surfaces by the
addition of base to the eluent. If the kind of base
(which should be nonnucleophilic and of a low
pKa) is chosen inadequately or the 5′-O-
FMOC-nucleoside-3′-O-phosphoramidite is
exposed to higher concentrations of base at
elevated temperatures, some loss of the protect-
ing group may occur during isolation, which
may lead to a danger of double couplings. The
authors therefore recommend (Lehmann et al.,
1989) repeated coevaporation of the derived
phosphoramidite fractions from toluene under
high vacuum followed by immediate precipita-
tion of the product. An evaluation of the less
basic N-morpholino phosphoramidite deriva-
tives (McBride and Caruthers, 1983) may be
advantageous in the present context.
From the more recent literature, two im-
provements to the FMOC strategy emerge as
particularly noteworthy. First, it was possible
to apply a safer protection of the phosphate
moiety by use of the allyl group as described
for a variety of solid-phase protocols by Hayak-
awa et al. (1990). Moreover it was found
(Bergmann et al., 1995) that the final deprotec-
tion conditions normally used for removal of
the base amino protecting groups (concentrated
ammonia, several hours at 55°C) simultane-
ously take off the allyl groups on the internu-
cleotide phosphate linkage. A second improve-
ment consists of the development of a different
linker unit to the solid support, which is of the
acetal type and hence is acid labile (2′,3′-O-
methylidene-4-phenoxyacetyl; Palom et al.,
1993). This allows cleavage of the FMOC
group under nucleophilic conditions (10%
piperidine in N,N-dimethylformamide) that are
significantly less basic and are therefore com-
patible with an oligonucleotide assembly via
methyl phosphoramidites. In addition, two re-
cently introduced alternatives to the FMOC
group (BSMOC and MSPOC; Carpino and
Mansour, 1999), which are cleaved with lower
concentrations of weak nucleophilic bases such
as piperidine or morpholine, may be particu-
larly well suited for this oligonucleotide assem-
bly scheme. The linker arm to the support
previously used by the authors (succinyl-sarco-
syl; Brown et al., 1989) is stable under strongly
basic conditions (up to 5% DBU in CH3CN),
but is cleaved by exposure to nucleophiles.
Finally, the authors would like to encourage
the exploitation of new chemistries potentially
compatible with the FMOC strategy. For in-
stance, it might be possible to combine the
photolabile o-nitrobenzyloxymethyl group
(Schwartz et al., 1992; Pitsch, 1997) with the
base-labile FMOC group to further increase the
scope of this remarkably versatile tool in the
chemical synthesis of biooligomers.
Critical Parameters and
Troubleshooting
The synthesis outlined in the Basic Protocol
is fairly short and straightforward. Other than
careful attention to basic organic synthesis
techniques, little troubleshooting advice needs
to be offered. Critical to achieving the expected
yields is strict adherence to the given reaction
and isolation conditions.
The syntheses of the starting materials are
considerably more involved, although the ex-
pected yields are quite good. Success is depend-
ent upon careful operational planning inherent
to multistep syntheses.
Anticipated Results
Following the synthesis strategy outlined in
the Basic Protocol, yields of between 52% and
65% can be achieved for ribonucleosides pro-
tected at the 5′ hydroxyl by FMOC, and 76%
can be achieved for 5′-O-FMOC-2′-deoxy-
thymidine. Similarly, good to excellent yields
are reported in the literature for deoxyguanos-
ine, deoxyadenosine, and deoxycytidine de-
rivatives (Balgobin and Chattopadhyaya, 1987;
Ma and Sonveaux, 1987). The four Support
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Protocols for the preparation of the starting
materials (2′-O-MTHP-protected ribonu-
cleosides) provide yields of ∼70%, except for
the synthesis of 2′-O-MTHP-2-N-isobutyryl-
guanosine, which provide a yield of ∼52%.
Time Considerations
The procedure described in the Basic Proto-
col may be carried out within 1 to 2 days starting
from 2′-O-MTHP-protected ribonucleosides.
The preparation of the MTHP-protected start-
ing intermediates can take 2 to 3 weeks per
nucleoside derivative. The authors suggest
starting with uridine (the simplest case) and
allowing time for crystallization of the 3′,5′-
diacetyl intermediate.
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